Bafna Pharmaceuticals
110.74
-0.58(-0.52%)
Market Cap₹261.97 Cr
PE Ratio-
IndustryHealthcare
Company Performance:
1D-0.52%
1M+2.45%
6M-35.88%
1Y+44.63%
5Y-10.77%
View Company Insightsright
More news about Bafna Pharmaceuticals
12Aug 25
Bafna Pharmaceuticals Reports Strong Q1 Results, Announces Key Leadership Changes
Bafna Pharmaceuticals Limited reported strong Q1 FY2026 results with a net profit of ₹338.89 lakhs, compared to a loss in the previous year. Revenue from operations increased by 4.02% to ₹3,462.40 lakhs. The company announced its 30th AGM for September 19, 2025, and approved re-appointments of two Independent Directors and the CEO. The Nomination and Remuneration Committee was reconstituted. Bafna Pharmaceuticals also achieved the prescribed Minimum Public Shareholding and completed the sale of assets from its Madhavaram manufacturing unit.
 no imag found
Bafna Pharmaceuticals
110.74
-0.58
(-0.52%)
1 Year Returns:+44.63%
Industry Peers
Sun Pharmaceutical
1,694.60
(+0.06%)
Divis Laboratories
5,821.00
(-0.61%)
Torrent Pharmaceuticals
4,011.60
(+0.61%)
Lupin
2,279.90
(+0.24%)
Dr Reddys Laboratories
1,217.80
(+0.04%)
Cipla
1,200.90
(+0.71%)
Zydus Life Science
866.30
(+0.24%)
Mankind Pharma
2,017.70
(+0.96%)
Aurobindo Pharma
1,340.40
(+0.50%)
Alkem Laboratories
5,236.50
(-0.41%)